MENU

Sirtex Medical soars 7% on Macquarie upgrade

Sirtex Medical (ASX: SRX), a biotech company that specialises in liver cancer treatments, jumped 7% higher to around $11 on Thursday after an upgrade from Macquarie.

“Macquarie rates SIRTEX MEDICAL as Outperform, with a price target of $14.30. Macquarie is very confident about the growth prospects for this company, not just in terms of market conditions but also clinical outcomes, new avenues for growth and the strategic direction.”

Sirtex shares have jumped 113% over the past year on the back of strong dose sales of its SIR-Spheres microspheres targeted radioactive liver cancer treatment. Although trading at a premium valuation, the future continues to look bright for Sirtex.

If you are looking for the next small cap stock to rocket higher, The Motley Fool’s FREE report titled Two Small Cap Superstars could be just for you. Click here now to access this free brand-new research report, including names, codes, and all the details of the two “superstars.”

More reading

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Motley Fool General Manager Bruce Jackson doesn’t own shares in any companies mentioned in this article.

 

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.